Non-alcoholic fatty liver disease (NAFLD) is increasingly diagnosed worldwide and is the most common cause of abnormal liver function tests and chronic liver disease in clinical practice. Although most patients with simple steatosis will have stable disease, 10--15 % with histologically proven non-alcoholic steatohepatitis (NASH) will progress to cirrhosis and its complications such as liver failure and hepatocellular carcinoma \[[@CR1]--[@CR3]\]. A long-term follow-up study of NAFLD patients showed that patients with NASH have lower survival rates compared to patients with simple steatosis, and most of the patients in the follow-up period developed type 2 diabetes or impaired glucose tolerance \[[@CR2]\]. Cirrhosis as a result of NAFLD is predicted to surpass chronic hepatitis C (CHC) as the leading indication for liver transplantation in the USA within the next 5 years, as the incidence of CHC is decreasing whereas that of NAFLD is increasing \[[@CR4]\].

Although cirrhosis is a major risk factor for hepatocellular carcinoma (HCC) development, a growing number of case reports and small patient series demonstrate that liver cancers sometimes develop in individuals with NAFLD who do not also have cirrhosis \[[@CR5]\]. The studies published in *Hepatology International* have provided further insight into the natural history of NAFLD and HCC. In this issue, Mohamad and colleagues \[[@CR6]\] carefully investigated the characterization of NAFLD-related HCC patients with or without cirrhosis. Thirty-six patients with NAFLD and HCC in NCL (HCC-NCL group) were identified and compared to 47 patients with NAFLD-HCC and liver cirrhosis (HCC-LC group). Liver fibrosis was not present in 55.9 % of patients in the HCC-NCL group (F0), stage 1 was present in 17.6 %, stage 2 in 8.8 % and stage 3 in 17.6 %. Lobular inflammation was present in 63.6 % of non-cirrhotic patients. Patients in the HCC-NCL were older (67.5 ± 12.3 vs. 62.7 ± 8.1 years), and less likely to be obese (52 vs. 83 %) or have type 2 diabetes (38 vs. 83 %), with *p* values \<0.05 for all. More interestingly, compared with the HCC-CL group, those in the HCC-NCL group were more likely to present with a single nodule (80.6 vs. 52.2 %), larger nodule size (\>5 cm) (77.8 vs. 10.6 %), and receive hepatic resection as the modality of HCC treatment (66.7 vs. 17 %), and were less likely to receive loco-regional therapy (22.3 vs. 61.7 %) or orthotopic liver transplantation (OLT) (0 vs. 72.3 %), with *p* values \<0.001 for all. These patients presented with larger tumors possibly because they did not receive regular medical check-ups due to their relatively preserved liver function. We have previously reported similar tumor characteristics in elderly HCC patients who also tended to have tumor markers with high DCP and low AFP \[[@CR7], [@CR8]\]. These results suggested that there might be a relationship between aging and HCC. Studying differences in tumor markers might be helpful in further understanding the tumor biology.

The authors also analyzed the prognosis of patients and found 86 % of patients without cirrhosis had HCC recurrence compared to only 14 % in patients with cirrhosis (*p* \< 0.001). One possible explanation is that these solitary tumors in the HCC-NCL group might have an aggressive tumor biology, although this result should be interpreted carefully because more cirrhotic patients might have undergone OLT and therefore presented with fewer recurrences than non-cirrhotic patients who might have undergone resection. Whether the recurrent tumor was intrahepatic metastases or de novo recurrence could be further investigated in pathological or genetic analysis. The HCC-NCL group was less likely to have obesity, type 2 diabetes and metabolic syndrome compared to the HCC-CL group, consistent with reports of the clinical features of NAFLD and HCC \[[@CR9]\]. The metabolic syndrome along with obesity and insulin resistance support several unique mechanisms that promote tumorigenesis. Understanding these pathways may have significant implications for pathogenesis and treatment and compel further investigation \[[@CR10], [@CR11]\]. Unadjusted analysis indicates that non-cirrhotics had worse survival with a mortality rate of 47 vs. 28 % in the CL group (*p* = 0.03); however, this difference in survival between the two groups was not significant after adjusting for age or OLT (*p* \> 0.05).

Although provocative, these data need to be treated with caution, as there are clear limitations in the study. Since these patients were not studied as a longitudinal cohort prior to HCC treatment, there is distinct selection bias. Patients with rapid progress of fibrosis and HCC may have died before the diagnosis. In addition, regarding the metabolic syndrome, poorly controlled patients may have died from other causes before HCC development. It is hard to evaluate the onset or duration of NAFLD; however, it would be of great interest to know the duration of the disease, specifically in F0 patients with HCC. Finally, since almost half of the patients underwent OLT, the survival rate does not reflect the true natural history of the disease. The survival curve did not decline over time and OLT could be beneficial for improving liver function and reducing the possibility of de novo recurrence of HCC. Longer follow-up data will be of interest.

Despite its inherent limitations, this manuscript suggests the nature of HCC arising in the context of NAFLD may be different from that arising from other forms of liver disease. As we are in the midst of an international epidemic of NAFLD and its major comorbidities, it is critical that we understand the implications of NAFLD for HCC. This knowledge will be necessary to develop optimal screening protocols, including risk scoring systems and treatment options: new rules of engagement may be required.
